Af­fimed hangs on­to Genen­tech al­liance af­ter drop­ping strand­ed PhI pro­gram as CSO ex­its

Sev­en months in­to the full clin­i­cal hold the FDA slapped on its Phase I AFM11 pro­gram fol­low­ing a pa­tient death, Af­fimed is scrap­ping the drug al­to­geth­er to fo­cus on two oth­er ear­ly-stage in­nate cell en­gagers — and it will be do­ing so, for now, with­out a CSO.

The Ger­man biotech made the de­ci­sion af­ter hear­ing from reg­u­la­tors ear­li­er this month that ad­di­tion­al da­ta would be re­quired be­fore they might re­sume work on the CD19/CD3-​tar­get­ing T cell en­gager said CEO Adi Hoess on a con­fer­ence call. Run­ning a nim­ble small biotech op­er­a­tion, he ex­plains, re­quires a com­mit­ment to the ef­fi­cient al­lo­ca­tion of time and re­sources.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.